Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Janssen, LP
Information provided by (Responsible Party):
Terence Friedlander, MD, University of California, San Francisco
ClinicalTrials.gov Identifier:
NCT01637402
First received: July 6, 2012
Last updated: June 24, 2014
Last verified: June 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2017
  Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)